Registered title, quoted from ClinicalTrials.gov
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by The University of Hong Kong–Shenzhen Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07663630, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Documented histological or cytologic diagnosis of NSCLC with each of the following:
Inclusion criterion 2
locally advanced, unresectable, stage III disease (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer TNM staging system); and
Inclusion criterion 3
Undergoing major surgery within 4 weeks prior to randomization or planned major surgical procedures during the study.
Exclusion criterion 9
Renal disease requiring dialysis or eGFR <30 mL/min/1.73 m².
Exclusion criterion 19
measurable disease at time of screening (assessment per RECIST v1.1); and
Inclusion criterion 4
Mixed small cell and non-small cell lung cancer histology.
Exclusion criterion 7
History of any secondary malignancy in the last 2 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ.
Exclusion criterion 12
Any Grade ≥3 pulmonary disease unrelated to underlying malignancy including, but not limited to:
Exclusion criterion 14
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: day-to-day activity level; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07663630, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Key Inclusion Criteria:
- Signed Informed Consent
- Documented histological or cytologic diagnosis of NSCLC with each of the following:
- locally advanced, unresectable, stage III disease (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer TNM staging system); and
- measurable disease at time of screening (assessment per RECIST v1.1); and
- must have completed platinum-based chemotherapy concurrent with radiation therapy, within 7 to 42 days prior to the randomization; and
- no evidence of progression of disease following definitive, platinum-based, concurrent chemoradiation therapy; and
- must be due to receive consolidation immunotherapy with durvalumab for up to 12 months, with the first dose of blinded study intervention to coincide with the first dose of durvalumab +/- 7 days; and
- absence of actional genomic mutations (eg, EGFR, ALK).
- Cachexia defined by Fearon criteria:
- BMI <20 kg/m2 and involuntary weight loss of >2% within 6 months prior to screening; or
- Involuntary weight loss of >5% over the past 6 months prior to screening irrespective of BMI
- Participant has been evaluated and determined that available anticachexic treatments have either been administered with no positive effect or the participant is not suitable for these treatments.
- Participants who are assessed by the investigator to have an ECOG PS ≤1.
Key Exclusion Criteria:
- Current active reversible causes of decreased food intake, as determined by the investigator. These causes may include, but are not limited to:
- NCI CTCAE Grade 3 or 4 oral mucositis
- Mechanical obstructions interfering with the participant's ability to eat
- Receiving tube feedings or having an ongoing clinical indication for parenteral nutrition (either total or partial) at the time of screening or randomization. Of note: short-term parenteral nutritional support for the management of acute, transient medical indications is allowed if discontinued prior to randomization.
- Any prior or current clinical diagnosis of heart failure, irrespective of left ventricular ejection fraction or New York Heart Association classification.
- Cachexia caused by reasons other than NSCLC, as determined by the investigator (eg, severe COPD).
- Mixed small cell and non-small cell lung cancer histology.
- Clinically significant ascites that requires medical intervention or underwent a paracentesis within 4 weeks prior to randomization.
- Undergoing major surgery within 4 weeks prior to randomization or planned major surgical procedures during the study.
- History of adrenal disorders (e.g. adrenal insufficiency, Cushing syndrome), pituitary adenoma or ectopic ACTH.
- Chronic use of systemic corticosteroid.
- History of any secondary malignancy in the last 2 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ.
- Symptomatic brain metastasis or leptomeningeal disease.
- Any Grade ≥3 pulmonary disease unrelated to underlying malignancy including, but not limited to:
- Severe asthma requiring systemic corticosteroids within 30 days prior to first dose of study intervention or not well controlled with low-dose inhaled corticosteroids/long-acting beta-2 agonists.
- Severe chronic obstructive pulmonary disease requiring supplemental oxygen or systemic corticosteroids.
- Clinically severe and/or Grade 4 pulmonary emboli within 3 months of the first dose of study intervention. Pulmonary emboli in main or lobar pulmonary arteries are also excluded.
- Any autoimmune or inflammatory disorders with significant pulmonary parenchymal involvement at time of screening (ie, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc).
- Renal disease requiring dialysis or eGFR <30 mL/min/1.73 m².
- History of severe liver disease or cirrhosis, unrelated to metastatic cancer. LFT abnormalities at the time of screening; confirmed by a single repeat test if deemed necessary: AST or ALT level ≥ 3 x ULN (>5 x ULN if liver involvement by the tumor), or total bilirubin level ≥ 1.5 x ULN (For Gilbert's syndrome, direct bilirubin > ULN is exclusionary).
- Left ventricular ejection fraction <50% on screening echocardiogram (or MUGA scan).
Quoted from ClinicalTrials.gov, NCT07663630, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07663630, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.